COMP <GO>
ABT vs UNH // GROSS PROFIT MARGIN
Abbott Laboratories (NYSE) VS. UnitedHealth Group Incorporated (NYSE) • 15-METRIC TALLY: ABT 7
— UNH 7
▲ GROSS PROFIT MARGIN LEADER: UNH
LAST: $110.16 (+3.73%) • MKT CAP: $190.62B
gross-margins
56.40%
LAST: $400.44 (-1.60%) • MKT CAP: $359.43B
gross-margins
88.31%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ABT VS. UNH)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ABT | UNH | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin ACTIVE | 56.40% | 88.31% | -31.91 | UNH | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 11.90% | 12.38% | -0.48 | UNH | /roic <GO> |
| EV/EBITDA & P/E Valuation | 18.4x | 15.3x | +3.13 | UNH | /valuation <GO> |
| Free Cash Flow Yield | 4.09% | 6.25% | -2.16 | UNH | /fcf-yield <GO> |
| Operating Margin | 18.20% | 5.32% | +12.88 | ABT | /operating-margins <GO> |
| Net Profit Margin | 14.70% | 3.53% | +11.17 | ABT | /net-margins <GO> |
| Revenue Growth (YoY) | 5.70% | 3.33% | +2.37 | ABT | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 2.27% | 2.29% | -0.02 | UNH | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 4.36 | 3.09 | +1.27 | ABT | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 7/9 | +1.00 | ABT | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | 7.00% | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 66.7 | 55.1 | +11.60 | ABT | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.99 | 0.33 | +0.66 | ABT | /macro-sensitivity <GO> |
| Forward P/E Multiple | 25.8x | 17.7x | +8.06 | UNH | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $190.62B | $359.43B | -$168.81B | UNH | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ABT REV | UNH REV | ABT GROSS % | UNH GROSS % | ABT FCF | UNH FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $44.33B | $447.57B | 56.4% | 88.7% | $7.39B | $16.07B |
| FY 2024 | $41.95B | $400.28B | 55.4% | 88.3% | $6.35B | $20.70B |
| FY 2023 | $40.11B | $371.62B | — | 89.6% | $5.46B | $25.68B |
| FY 2022 | — | $324.16B | — | 89.6% | — | $23.40B |
| FY 2021 | — | $287.60B | — | 89.2% | — | $19.89B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ABT // BETA 0.99
UNH // BETA 0.33